Sally C. Pipes

Commentary

The New Medicine Tariffs Are a Prescription for Disaster

President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary

How innovation saves lives: What America’s pharmaceutical ecosystem gets right

When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary

The rural hospital rescue fund is a fraud

Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Commentary

What’s The GLP-1 Black Market, How Big a Threat Is It?

A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary

Generics Must Compete On Price, Not Safety

America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
Commentary

The Trump Administration Is Reviving Its Worst Drug Pricing Policies

It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Commentary

Is a Primary Care Revolution Dawning?

Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Commentary

Let the Obamacare subsidies expire

As members of Congress return to their districts this month, they may receive earfuls about extending the Biden administration‘s enhanced subsidies for Obamacare, which are scheduled to expire at the end of this year. Pundits warn that, unless Congress extends the subsidies, premiums in the individual market could increase by ...
Commentary

Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.

Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Commentary

Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative

Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Commentary

The New Medicine Tariffs Are a Prescription for Disaster

President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary

How innovation saves lives: What America’s pharmaceutical ecosystem gets right

When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary

The rural hospital rescue fund is a fraud

Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Commentary

What’s The GLP-1 Black Market, How Big a Threat Is It?

A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary

Generics Must Compete On Price, Not Safety

America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
Commentary

The Trump Administration Is Reviving Its Worst Drug Pricing Policies

It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Commentary

Is a Primary Care Revolution Dawning?

Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Commentary

Let the Obamacare subsidies expire

As members of Congress return to their districts this month, they may receive earfuls about extending the Biden administration‘s enhanced subsidies for Obamacare, which are scheduled to expire at the end of this year. Pundits warn that, unless Congress extends the subsidies, premiums in the individual market could increase by ...
Commentary

Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.

Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Commentary

Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative

Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Scroll to Top